Immix Biopharma, Inc. (IMMX) Stock Forecast
IMMX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $24.30 average of analyst targets
- Upside to target
- +204.5% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.19
- 52-week range
- $3.03 – $14.47
IMMX analyst ratings
7 analystsNumber of analysts at each rating.
IMMX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMMX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.21 | −$0.17 | −$0.24 | +21.4% | 7 |
| Current fiscal year (2026) | −$0.71 | −$0.77 | −$0.51 | −$0.89 | +19.8% | 8 |
| Next fiscal year (2027) | −$0.85 | −$1.45 | −$0.20 | −$0.71 | −18.7% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMMX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $27.9M | $0 | $93.9M | 0.0% | 6 |
IMMX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMMX revenue: reported and forecast
IMMX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.18 | −$0.19 | −$0.19 | −$0.19 | +9.8% | 0 up · 2 down |
| Current fiscal year (2026) | −$0.69 | −$0.70 | −$0.74 | −$0.72 | −$0.71 | +3.2% | 2 up · 1 down |
| Next fiscal year (2027) | −$0.74 | −$0.84 | −$0.90 | −$0.86 | −$0.85 | +14.3% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMMX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMMX beat in 7 of 12.
What analysts expect from IMMX
7 analysts cover Immix Biopharma; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.30, 204.5% above the latest close of $7.98. Analysts expect earnings of −$0.71 per share for 2026, +19.8% from a year earlier. For 2027 the average estimate is −$0.85 per share on revenue of $27.9 million. Immix Biopharma beat the EPS estimate in 7 of the last 12 quarters.
Related: IMMX income statement, IMMX key metrics, IMMX chart. See the IMMX stock overview for the latest quote and news.
IMMX forecast FAQ
What is Immix Biopharma's price target?
The average analyst price target for Immix Biopharma is $24.30, 204.5% above the latest close of $7.98.
Is Immix Biopharma a buy, hold or sell?
Of 7 analysts covering Immix Biopharma, 4 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immix Biopharma's EPS forecast?
Analysts forecast −$0.71 per share for 2026 (range −$0.77 to −$0.51); for 2027 the estimate is −$0.85.
When does Immix Biopharma report earnings?
Immix Biopharma is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 after the market closes; the EPS estimate is $-0.19.
Does Immix Biopharma usually beat earnings estimates?
Immix Biopharma reported EPS at or above the analyst estimate in 7 of the last 12 quarters.